{
    "clinical_study": {
        "@rank": "34976", 
        "arm_group": {
            "arm_group_label": "SP-02L", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy\n      in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL)."
        }, 
        "brief_title": "A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral T-cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Korean patients aged \u2265 20 years of age at the day of obtaining the informed consent\n\n          -  Patients with histologically confirmed diagnosis of the following:\n\n               -  PTCL, not otherwise specified (PTCL-NOS)\n\n               -  Anaplastic Large Cell Lymphoma (ALCL ALK-positive/negative)\n\n               -  Angioimmunoblastic T-cell Lymphoma (AITL)\n\n          -  Have relapsed or refractory to at least one prior systemic chemotherapy for the above\n             disease (currently requiring therapy)\n\n          -  Have at least 1 evaluable lesion\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n\n          -  Life expectancy of at least 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689220", 
            "org_study_id": "SP-02L03"
        }, 
        "intervention": [
            {
                "arm_group_label": "SP-02L", 
                "description": "Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle).  Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.", 
                "intervention_name": "SP-02L (darinaparsin for injection)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SP-02L", 
                "description": "Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.", 
                "intervention_name": "SP-02L (darinaparsin for injection)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of dose-limiting toxicity and adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 or 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689220"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor response (overall response)", 
                "safety_issue": "No", 
                "time_frame": "2 and 4 cycles"
            }, 
            {
                "description": "Cmax, Area under curve, Tmax, t1/2, Clearance and Volume of distribution", 
                "measure": "Plasma concentration-time profile", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 8 hours post-dose on Day 1 and 5, and 0 hour on Day 2, 3, 4, 6, 8 and 15"
            }
        ], 
        "source": "Solasia Pharma K.K.", 
        "sponsors": {
            "collaborator": {
                "agency": "Synex Consulting Korea Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Solasia Pharma K.K.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}